27th ANNUAL
New Treatments in Chronic Liver Disease

MARCH 30 - APRIL 1, 2012
Pre-Conference: Friday, March 30, 2012
Main Conference: Sat., March 31 – Sun., April 1, 2012
Hyatt Regency La Jolla at Aventine, San Diego, California
Course Overview

This CME conference will review new medications and therapies that are available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, Wilson's Disease, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There will be a fundamental change in treatment of chronic renal hepatitis C in 2012 with the addition of direct-acting antiviral (DAAs) drugs to current standard of care. There will be three separate lectures devoted to this topic this year. The first will be on triple therapies which will be approved in 2012. The remaining two will be on future therapies using two or more DAAs, with or without interferons.

We anticipate that there will be a number of demands placed on treatment providers which will be new, including different pretreatment predictors, viral resistance monitoring, rash and anemia management, and learning different therapeutic regimens. Looking beyond 2012, we see numerous combinations of DAA's in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and NS5A inhibitors. All of these agents are entering phase 3 development rapidly. In hepatitis B, the treatments have not changed but there are more mature data available on renal resistance, long-term HBsAg loss and clinical outcomes. New therapies for NAFLD and NASH are in development and will be explored. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on Wilson's disease and the management of pulmonary and cardiac complications in the transplant candidate.

Educational Objectives

After participating in this course, attendees should be able to:

- Understand the details of new AASLD guidelines for treatment of HCV using DAAs in combination with pegylated interferon and ribavirin
- Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
- Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals.
- Discuss novel therapies for HCV including NSSA, protease and polymerase inhibitors and cyclophilin inhibitors.
- Update the skills and management required for transplant hepatology.
- Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
- Discuss new treatment paradigms for HCV direct-acting antiviral drugs.
- Recognizing the impact of NAFLD and NASH in the US and consider new treatment options for these patients.
- Describe the diagnosis and treatment of PBC and PSC.
- Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
- Discuss the issues complicating drug treatment in decompensated hepatic C, hepatic encephalopathy and the use of liver assist devices.
- Review the management of Wilson’s Disease and the pulmonary/cardiac complications of ESLD.

2012 Conference Highlights

- New! Half Day Pre-Conference Seminar reviewing the virology, genotypes and modes of infection of HCV. Participants will learn the details of new AASLD guidelines for treatment of HCV using DAAs in combination with pegylated interferon and ribavirin.
- Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
- Controversies presented on the treatment of 1L28B CC patients with DAAs, NASH and the use of DAAs in Post-Transplant HCV.
- Audience Response System incorporated for instant feedback and interactive learning.
- Endorsed by the American College of Gastroenterology.
- Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.

Accreditation

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum number of 10.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Documentation of awarded credit is provided for registered attendees in exchange for completed activity evaluation. Certificates of attendance are available, upon request, at the end of the course.

Nurses: The California State Board of Registered Nurses (BRN) accepts AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Most state Boards of Registered Nurses accept AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Nurses should check with their state board regarding use of CME credit.

Nurse Practitioners: This program is approved for 13.25 contact hours of continuing education by the American Academy of Nurse Practitioners. Program ID 1111361

Physicians Assistants: The American Academy of Physician Assistants accepts Category 1 credit from AMA Category 1 CME organizations accredited by ACCME.

Pharmacists: This conference meets CE Standards for Pharmacists by the California State Board of Pharmacy.

Educational Grants

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time of printing, a complete listing of commercial supporters was not available. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

Cultural and Linguistic Competency

This activity is in compliance with California Assembly Bill 1195 which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency. The intent of this bill is to ensure that health care professionals are able to meet the cultural and linguistic concerns of a diverse patient population through effective and appropriate professional development. Cultural and linguistic competency was incorporated into the planning of this activity.

Target Audience

- Hepatologists
- Infectious Disease Specialists
- Physician Assistants
- Residents/fellows
- Gastroenterologists
- Nurse Practitioners
- Nurses
- and others desiring an update in these specialty areas
We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treatment with telaprevir and boceprevir, manage of side effects of rash and hematologic complications of therapy and deal with various patient populations including African Americans, HIV-coinfected and ESLD patients. Lastly, new drugs in development including protease inhibitors, nucleoside and non-nucleoside polymerase inhibitors, NSSA inhibitors, and other novel agents will be discussed.

PRE-CONEFERENCE OVERVIEW

Friday, March 30, 2012

12:30 p.m. Registration
1 p.m. Welcome & Introduction
   Paul Pockros, MD
1:10 p.m. Review of Viral Hepatitis, Discovery of HCV and Natural History
   Tarek Hassanein, MD
1:40 p.m. Diagnostic Testing, Histology, Cirrhosis and Liver Biopsy
   Tarek Hassanein, MD
2:10 p.m. Telaprevir and Boceprevir: How to Use Them
   Paul Pockros, MD
2:40 p.m. Break
3 p.m. Special Populations-HIV, ESLD, Post-Transplant
   Tarek Hassanein, MD
3:30 p.m. Case Presentation, Discussion and Q&A
   • Side-Effects Management
   • Selection of Treatment
   • Cirrhosis: Who to Treat
   • Special Populations
   Paul Pockros, MD, Andrea Scherschel, NP
5 p.m. Adjourn

MAIN CONFERENCE

Saturday, March 31, 2012

10:15 a.m. New Directions for HCV Therapy (2012-2016)
   Paul Pockros, MD
11 a.m. Panel: New Directions for HCV Therapy Beyond 2016: Our Opinions
   Adrian Di Bisceglie, MD
   Anna Lok, MD and
   Paul Pockros, MD
11:30 a.m. Panel Discussion: Morning Speakers
Noon Lunch

NON-HEPATITIS LIVER DISORDERS
Moderator: Paul Pockros, MD

11:40 a.m. Update on Medical Therapies for PBC and PSC
   Keith Lindor, MD
1:50 p.m. Update on Wilson's Disease
   Michael Schilsky, MD
3:10 p.m. Break & View Exhibits

Controversy
Treat NASH with Proglitazone, Vitamin E or Neither?
3:30 p.m. Proglitazone?: Michael Schilsky, MD
3:35 p.m. Vitamin E?: Michael Schilsky, MD
3:40 p.m. Neither?: Keith Lindor, MD
3:45 p.m. Drug Induced Liver Disease
   Willis Maddrey, MD
4 p.m. Panel Discussion: Afternoon Speakers
4:30 p.m. Adjourn

Sunday, April 1, 2012

7:30 a.m. Breakfast & View Exhibits
8 a.m. Management of ESLD Patient
   Michael Schilsky, MD
8:40 a.m. Hepatocellular Carcinoma
   Adrian Di Bisceglie, MD
9:20 a.m. Pulmonary and Cardiac Disorders in the Transplant Candidate
   Norman Sussman, MD
10 a.m. Break & View Exhibits

Controversy
Should We Use DAAs in Post-Transplant HCV Now?
10:20 a.m. Yes: Michael Schilsky, MD
10:25 a.m. No: Paul Pockros, MD
10:30 a.m. Liver Support Devices in 2012
   Tarek Hassanein, MD
11:20 a.m. Panel Discussion: Morning Speakers
Noon Adjournment
William S. Haubrich Distinguished Lecturer

Anna Suk-Fong Lok, MD

Anna Suk-Fong Lok, MD is the Alice Lohman Andrews Research Professor in Hepatology at the Department of Internal Medicine at the University of Michigan Health System in Ann Arbor, Michigan, USA. Dr. Lok is also Director of Clinical Hepatology and Associate Chair for Clinical Research in the Department of Internal Medicine.

Dr. Lok obtained her medical degree from University of Hong Kong in Hong Kong and her hepatology training under the late Dame Sheila Sherlock at the Royal Free Hospital in London, UK. She was a faculty at the University of Hong Kong until she moved to the United States in 1992. Dr. Lok’s research focuses on the natural history and treatment of hepatitis B and C, and prevention of hepatocellular carcinoma. Her research is funded by the National Institutes of Health, private foundations, and various pharmaceutical companies. She has published more than 300 papers on viral hepatitis and liver diseases and is the co-author of the American Association for the Study of Liver Diseases Association Guidelines on “Hepatitis B.” Dr. Lok has trained more than 30 fellows and junior faculty from all over the world, some of whom have risen to the ranks of full professors and directors of liver programs in their home country. Dr. Lok received many awards throughout her career. Recent awards include the Distinguished Scientist Award from the Hepatitis B Foundation in the USA and the Distinguished Women Scientist from the American Gastroenterological Association in 2008. Dr. Lok will receive the Distinguished Service Award from the American Association for the Study of Liver Diseases during its annual meeting in November, 2011.

Dr. Lok served as Associate Editor of HEPATOLOGY in 2001-6 and Co-Editor of Journal of Viral Hepatitis in 2007-9. She is currently a Senior Associate Editor of GASTROENTEROLOGY. Dr. Lok has made important contributions to raising awareness of hepatitis B among the Asian-American communities and Asian-American physicians. She is one of the founders of the Asian Health Foundation and is currently a member of the Executive Board.

William S. Haubrich, MD

Dr. Haubrich graduated from Franklin & Marshall College in Lancaster, Pennsylvania in 1943 and from the medical school of Case-Western Reserve University in Cleveland, Ohio in 1947. His postgraduate training in pathology and internal medicine was at Cleveland City Hospital (now MetroHealth). His mentor in gastroenterology was Dr. Henry L. Bockus at the Graduate Hospital of the University of Pennsylvania in Philadelphia. During the Korean War he served as gastroenterologist to the Madigan Army Hospital at Fort Lewis, Washington. From 1955 to 1970 he was on the gastroenterology staff at the Henry Ford Hospital in Detroit. In 1970 he was appointed Clinical Member at the Scripps Clinic and Research Foundation where he headed the division of gastroenterology from 1972 to 1984. He has served as Clinical Professor of Medicine at the University of California, San Diego since 1971. His scholarly contributions include more than 200 journal articles and textbook chapters. He was consultant in life sciences to the editors of the 3rd and 4th editions of the American Heritage Dictionary of the English Language. In 1960 he was awarded the Vincent Lyon Prize by the American Gastroenterology Association and in 1985 received the Rudolf Schindler Award of the American Society of Gastrointestinal Endoscopy. He has been named a Master of the American College of Physicians.
Pre-Conference Fees

Space is limited, so register early!

Included: Course tuition, break and course syllabus.
Not Included: Travel costs, parking, lodging and meals.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 29</th>
<th>Mar 1 - Mar 27</th>
<th>On-site after Mar 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians/Nurses/Nurse Practitioners/Physician Assistant/Pharmacist/Allied Health Professionals/Fellows and Residents</td>
<td>$75</td>
<td>$100</td>
<td>$125</td>
</tr>
</tbody>
</table>

Main Conference Fees

Included: Course tuition, breakfasts, breaks, lunch and the course syllabus.
Not Included: Travel costs, parking, lodging and dinners.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 29</th>
<th>Mar 1 - Mar 27</th>
<th>On-site after Mar 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$255</td>
<td>$280</td>
<td>$305</td>
</tr>
<tr>
<td>Nurses/Nurse Practitioners/Physician Assistant/Pharmacist/Allied Health Professionals</td>
<td>$185</td>
<td>$210</td>
<td>$235</td>
</tr>
<tr>
<td>Fellows and Residents</td>
<td>$115</td>
<td>$140</td>
<td>$165</td>
</tr>
</tbody>
</table>

Please note: there are no day rates available for this conference.

By completing this registration form and returning it to Scripps you are acknowledging compliance with all attendance policies.

Please Print Clearly. Should we have any conference communications or updates please provide your direct contact information.

FIRST NAME, MI, LAST NAME

DEGREE (MD, DO, PhD, RN, ETC)

BADGE NAME (IF DIFFERENT FROM ABOVE)

AFFILIATION/HOSPITAL/COMPANY

SPECIALTY

DIRECT MAILING ADDRESS

CITY/STATE/ZIP CODE

DIRECT TELEPHONE

FAX

EMAIL

ASSISTANT NAME ASSISTANT DIRECT TELEPHONE

ASSISTANT E-MAIL

Please indicate any special needs (including dietary restrictions)

Special requests will be considered and accommodated in full compliance with the Americans with Disabilities Act (ADA).

Office Use Only:

Date Received

Amount

Check No. / Approval CD

Confirmation Sent

Initials

Payment Method

☐ Check  Please make checks payable to Scripps (in U.S. dollars only).

If paying by credit card, please fill out the information below.

□ Visa  ☐ MasterCard  ☐ Amex  ☐ Discover

CREDIT CARD NUMBER

EXPIRATION DATE  SECURITY CODE ON CARD (required)

NAME ON CARD

AUTHORIZED SIGNATURE

BILLING ADDRESS IF DIFFERENT FROM ABOVE

Exhibit and Support Opportunities

For information on exhibit and support opportunities during this and many other Scripps educational conferences, please contact:

Scripps Conference Services & CME  •  858-652-5400

med.edu@scrippsshealth.org  •  www.scripps.org/conferenceservices
27th Annual
New Treatments in Chronic Liver Disease

MARCH 30 - APRIL 1, 2012

Pre-Conference: Friday, March 30, 2012
Main Conference: Saturday, March 31 – April 1, 2012
Hyatt Regency La Jolla, San Diego, California

2012 Conference Highlights

• New! Half Day Pre-Conference Seminar reviewing the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections.

• Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.

• Controversies presented on the treatment of IL28B CC patients with DAAs, NASH and the use of DAAs in Post-Transplant HCV.

• Audience Response System incorporated for instant feedback and interactive learning.

• Endorsed by the American College of Gastroenterology.

• Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.

Target Audience

• Hepatologists
• Gastroenterologists
• Infectious Disease Specialists
• Physician Assistants
• Nurses
• Residents/Fellows
• and others desiring an update in these specialty areas

New This Year:
March 30th Pre-Conference Seminar!